Drug recall · November 20, 2019
GSMS: Ranitidine Capsules 150 mg recall
Why: CGMP Deviations: Presence of NDMA impurity detected in product.
Class II: could cause temporary or reversible health problems; serious harm is remote.
The recall
- Product
GSMS: Ranitidine Capsules 150 mg, Rx only, 500 count bottles (NDC 51407-097-05) Manufactured by Novitium Pharma LLC, 70 Lake Drive, East Windsor, New Jersey 08520; Packaged by GSMS, Incorporated, Carmillo, CA 93012 USA.
- Lots / codes
Lot Codes: GS023970, Exp. 10/31/2020; GS026108, Exp. 10/31/2020;GS026099, Exp. 10/31/2020; GS026838, Exp. 10/31/2020; GS025702, Exp. 10/31/2020; GS027272, Exp. 10/31/2020; GS027273, Exp. 05/31/2021.
- Quantity
- N/A
- Company
- Golden State Medical Supply Inc., Camarillo, CA
- Distribution
- AZ, IA, MA, MO
- Initiated
- November 6, 2019 · Voluntary: Firm initiated
- Classified
- November 10, 2019
- Reported
- November 20, 2019
- Ended
- April 15, 2021
- How notified
- Letter
The drug: prices, other makers, shortages
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.
Watch Ranitidine
One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.